Clinical Management of Hemodialyzed Patients: From Pharmacological Interventions to Advanced Technologies
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nephrology & Urology".
Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 8755
Special Issue Editor
Interests: chronic kidney disease; acute kidney injury; biomarkers; hemodialysis; immune disfunction in uremic patients; oxidative stress in dialysis; sepsis; septic shock and blood purification
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Uremic toxins represent independent risk factors for the mortality of hemodialyzed (HD) patients, as they are poorly removed through conventional, diffusive techniques.
Several studies have associated middle toxin molecules with the pathological features of uremia, such as immune dysfunction and inflammation, as well as adverse outcomes in HD patients.
Systemic inflammation plays a pivotal role in morbidity and mortality in these patients, contributing to atherosclerosis, cardiovascular disease, and anemia. Furthermore, immune deficiency leads to impaired response to vaccination and increased incidence, severity, and poor outcome of microbial infections.
These two entities are not mutually exclusive, but they could represent two sides of the same coin. In fact, uremic-associated inflammation is closely related to the activation of the innate immune system. Recently, medium cut-off (MCO) dialyzers have utilized a novel class of membranes designed to increase the removal of larger middle molecules in HD, demonstrating non-inferior results when compared with diffusive-convective techniques.
The aim of this Special issue is to carry out an in-depth analysis of pharmacological interventions and new technologies applied to HD patients, designing clinical management based on a personalized medicine.
Papers evaluating new biomarkers of inflammation and altered immunity status in HD patients, as well as noninvasive devices able to detect biological data in real time, are welcome.
Dr. Paolo Monardo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hemodialysis
- renal biomarkers
- biotechnologies
- inflammation
- immune dysfunction
- HD-related comorbidities
- real-time monitoring